康希諾(06185.HK)漲逾9% 據報旗下一針疫苗在廣東開打
據報由康希諾生物-B(06185.HK)生產的重組新冠病毒疫苗已先後在廣州、深圳開始使用。康希諾回吐兩天守穩50天線之上,今天股價顯著回升,午後高見367元,創逾一個月高,現造365.8元,急漲9.2%,成交倍增至236萬股,涉資8.36億元。
《新浪財經》引述消息指,由康希諾生產的重組新冠病毒疫苗(5型腺病毒載體)已先後在廣州、深圳開始使用。該疫苗只需接種1劑,由軍事科學院陳薇院士團隊和康希諾生物合作研發,是首家獲批的國產腺病毒載體新冠病毒疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.